Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
2.
Biomed J ; 44(5): 582-588, 2021 10.
Article in English | MEDLINE | ID: mdl-34371224

ABSTRACT

BACKGROUND: Unequal access to healthcare is a global medical problem. Telemedicine, recently made possible by technological advances, may mitigate this inequity. However, the usefulness of telemedicine for procedure-driven disciplines, such as otolaryngology, under infectious conditions (e.g., the COVID-19 pandemic) is unknown. METHODS: Telemedicine was made legal in Taiwan by an amendment to the Physician Act in 2018. Kaohsiung Chang Gung Memorial Hospital was the first hospital in Taiwan to provide the telemedicine service by connecting to the Chenggong Branch of Taitung Hospital (CGBTH) in November 2018. This retrospective cohort study included all new and established otolaryngology outpatient consultations between November 2018 and May 2020 at CGBTH. The Current Procedural Terminology and International Classification of Disease, 10th Revision codes, patient demographic data, and questionnaire data were obtained. RESULTS: The study included 123 patients with 218 encounters over 19 months. The majority of complaints were ear-related (52.6%). Overall, 49% of the encounters required a specialized procedure for diagnosis and treatment; of these, cerumen removal was the most common procedure. The patient subjective improvement rate increased over the study period (from 62.0% to 78.9%). The rates of return and case closure were both around 90% in 2018 and 2019. The number of otolaryngology consultations and rate of return declined after the start of the COVID-19 pandemic; however, the subjective improvement and case closure rates remained stable. The telemedicine service saved at least 2 h driving time per visit. CONCLUSION: Telemedicine for otolaryngology is a promising approach for remote and underserved regions, as well as during an infectious disease pandemic.


Subject(s)
COVID-19 , Otolaryngology , Telemedicine , Humans , Pandemics , Retrospective Studies , SARS-CoV-2 , Taiwan/epidemiology
3.
Front Neurol ; 11: 584446, 2020.
Article in English | MEDLINE | ID: mdl-33240207

ABSTRACT

Objective: To explore the effectiveness and safety of mycophenolate mofetil (MMF) as a second-line medication in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, the most common and severe autoimmune encephalitis. Methods: The clinical data of six children with anti-NMDAR encephalitis admitted to the First Hospital of Jilin University were retrospectively analyzed, and the effectiveness and safety of MMF were evaluated. Results: Six children with anti-NMDAR encephalitis were treated with MMF in the 2nd or 3rd treatment disease event (3 cases vs. 3 cases). MMF initiation was mean 19.2 months (range 6-39 months) after disease onset at a mean dose of 25.6 mg/kg (range 19.6-28.4 mg/kg) for 14 months (range 6-26 months). Only two patients had transient mild diarrhea within 2 weeks of MMF application. During follow-up, one patient relapsed whilst on MMF, one patient discontinued MMF, and 4 cases were still on MMF. Conclusion: The use of MMF in anti-NMDAR encephalitis may be effective and safe. MMF can be used as one of the relapse prevention options in patients who already have relapsed or possibly even after the first event. Delayed use may be the main reason for MMF failure.

4.
BMC Pediatr ; 20(1): 516, 2020 11 10.
Article in English | MEDLINE | ID: mdl-33172428

ABSTRACT

BACKGROUND: Benign convulsions with mild gastroenteritis (BCWG) is a common condition in children in Asia and is generally not associated with pH or electrolyte imbalances. When BCWG is diagnosed, a lumbar puncture is usually recommended to rule out potential intracranial infections. This study examined the clinical characteristics of BCWG and evaluated the necessity of lumbar puncture. METHODS: Medical records of children admitted to the First Hospital of Jilin University with BCWG between January 2018 and May 2019 were reviewed and analyzed. Children were stratified by rotavirus positivity or lumbar puncture status. Clinical characteristics and long-term outcomes were compared between groups. RESULTS: A total of 51 children were included in the analyses (55.1% rotavirus [HRV] positive). The average age of convulsion onset was 21.12 ± 7.44 months, the male-to-female ratio was 1.8:1, and convulsions occurred primarily between October 2018 and April 2019. The main clinical presentations of BCWG were convulsions, vomiting, diarrhea, and fever. Convulsions occurred predominantly two days after diagnosis of gastroenteritis, were mainly generalized tonic-clonic with 88.2% of children having ≤ 3 convulsions per episode, and had a mean duration of 2.0 minutes (interquartile range [IQR]: 1.0, 3.0). Children with BCWG had mild metabolic acidosis (HCO3- 17.82 ± 3.63 mmol/L) with an elevated anion gap (AG; 20.98 ± 3.00 mmol/L), mild hyponatremia (134.56 ± 2.85 mmol/L), and slightly increased levels of creatine kinase myocardial band (CKMB). HRV + children had more severe acidosis and higher CKMB levels. Cerebrospinal fluid (CSF) samples collected via lumbar puncture were normal. No developmental abnormalities were noted as assessed by the Social Life Ability Scale. CONCLUSIONS: BCWG is a situation-related seizure, with clinical presentations of tonic-clonic or focal convulsions and mild gastroenteritis (vomiting, diarrhea). Mild metabolic acidosis and hyponatremia may exist. The prognosis of the disease is favorable; lumbar puncture and long-term antiepileptics are unnecessary and should not be recommended.


Subject(s)
Gastroenteritis , Rotavirus Infections , Asia , Child , Child, Preschool , Female , Gastroenteritis/complications , Gastroenteritis/diagnosis , Gastroenteritis/therapy , Humans , Infant , Male , Retrospective Studies , Seizures/diagnosis , Seizures/etiology
5.
Neural Regen Res ; 14(12): 2126-2131, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31397351

ABSTRACT

The specific mechanisms by which acupuncture affects the central nervous system are unclear. In the International Standard Scalp Acupuncture system, acupuncture needles are applied at the middle line of the vertex, anterior parietal-temporal oblique line, and the posterior parietal-temporal oblique line. We conducted a single-arm prospective clinical trial in which seven healthy elderly volunteers (three men and four women; 50-70 years old) received International Standard Scalp Acupuncture at MS5 (the mid-sagittal line between Baihui (DU20) and Qianding (DU21)), the left MS6 (line joining Sishencong (EX-HN1) and Xuanli (GB6)), and the left MS7 (line joining DU20 and Qubin (GB7)). After acupuncture, resting-state functional magnetic resonance imaging demonstrated changes in the fractional amplitude of low frequency fluctuations and regional homogeneity in various areas, showing remarkable enhancement of regional homogeneity in the bilateral anterior cingulate, left medial frontal gyrus, supramarginal gyrus, right middle frontal gyrus, and inferior frontal gyrus. Functional connectivity based on a seed region at the right middle frontal gyrus (42, 51, 9) decreased at the bilateral medial superior frontal gyrus. Our data preliminarily indicates that the international standard scalp acupuncture in healthy elderly participants specifcally enhances the correlation between the brain regions involved in cognition and implementation of the brain network regulation system and the surrounding adjacent brain regions. The study was approved by the Ethics Committee of the China-Japan Union Hospital at Jilin University, China, on July 18, 2016 (approval No. 2016ks043).

6.
Am J Physiol Endocrinol Metab ; 315(4): E435-E445, 2018 10 01.
Article in English | MEDLINE | ID: mdl-29763375

ABSTRACT

The human (h) placental lactogenic hormone chorionic somatomammotropin (CS) is highly produced during pregnancy and acts as a metabolic adaptor in response to maternal insulin resistance. Maternal obesity can exacerbate this "resistance", and a >75% decrease in CS RNA levels was observed in term placentas from obese vs. lean women. The genes coding for hCS ( hCS-A and hCS-B) and placental growth hormone ( hGH-V) as well as the hCS-L pseudogene and pituitary growth hormone (GH) gene ( hGH-N) are located at a single locus on chromosome 17. Three remote hypersensitive sites (HS III-V) located >28 kb upstream of hGH-N as well as local hCS gene promoter and enhancer regions are implicated in hCS gene expression. A placenta-specific chromosomal architecture, including interaction between HS III-V and hCS but not hGH gene promoters, was detected in placentas from lean women (BMI <25 kg/m2) by using the chromosome conformation capture assay. This architecture was disrupted by pre-pregnancy maternal obesity (BMI >35 kg/m2), resulting in a predominant interaction between HS III and the hGH-N promoter, which was also observed in nonplacental tissues. This was accompanied by a decrease in hCS levels, which was consistent with reduced RNA polymerase II and CCAAT/enhancer-binding protein-ß association with individual hCS promoter and enhancer sequences, respectively. Thus, pre-pregnancy maternal obesity disrupts the placental hGH/CS gene locus chromosomal architecture. However, based on data from obese women who develop GDM, insulin treatment partially recapitulates the chromosomal architecture seen in lean women and positively affects hCS production, presumably facilitating prolactin receptor-related signaling by hCS.


Subject(s)
Chromosomes, Human/genetics , Growth Hormone/genetics , Human Growth Hormone/genetics , Obesity/genetics , Placenta/metabolism , Placental Hormones/genetics , Placental Lactogen/genetics , Pregnancy Complications/genetics , Body Mass Index , Chromatin Immunoprecipitation , Chromosomes, Human/metabolism , Female , Gene Expression , Growth Hormone/metabolism , Human Growth Hormone/metabolism , Humans , Immunoblotting , Insulin Resistance , Obesity/metabolism , Placental Hormones/metabolism , Placental Lactogen/metabolism , Pregnancy , Pregnancy Complications/metabolism , Promoter Regions, Genetic , Pseudogenes , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction
8.
Ann Med ; 49(5): 421-434, 2017 08.
Article in English | MEDLINE | ID: mdl-28293967

ABSTRACT

OBJECTIVE: Rasagiline is a second-generation potent selective inhibitor of monoamine oxidase-B. The aim of the study was to analyze the effectiveness of rasagiline in treatment of Parkinson's disease (PD), both as monotherapy and combination therapy. METHODS: Medline, Cochrane, EMBASE, and Google Scholar databases were searched until 9 March 2016 using the keywords: Rasagiline, Azilect, Parkinson's disease. Randomized controlled trials of patients with PD who were randomized to treatment with rasagiline or placebo were included. Outcomes were unified Parkinson's disease rating scale (UPDRS) and the three subscales. RESULTS: Ten studies fulfilled the inclusion criteria and 2709 patients were evaluated. The overall analysis revealed a significant improvement in change of total UPDRS scores in 1 mg/day and 2 mg/day rasagiline groups compared to placebo. Significant improvement in Part I (Mentation) of UPDRS scores was observed in 1 mg/day, but not in 2 mg/day rasagiline treatment group. Part II (ADL) and Part III (Motor) subscales significantly improved with both doses of rasagiline. Both monotherapy and combination therapy significantly improved total UPDRS scores. CONCLUSIONS: Our results confirm the efficacy of rasagiline in PD. Further studies are required to establish the optimal dose of rasagiline, as well as to determine its effectiveness in different combination therapy protocols. KEY MESSAGES Rasagiline treatment was associated with significant improvement of UPDRS scores and the scores of the subscales. Both monotherapy and combination therapy significantly improved total UPDRS scores. Effect of rasagiline on total UPDRS scores was not dose-dependent.


Subject(s)
Indans/administration & dosage , Monoamine Oxidase Inhibitors/administration & dosage , Parkinson Disease/drug therapy , Aged , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Severity of Illness Index , Treatment Outcome
9.
Oncotarget ; 8(65): 109752-109761, 2017 Dec 12.
Article in English | MEDLINE | ID: mdl-29312645

ABSTRACT

AIM: To study the diagnostic and prognostic role of serum galectin-1 (Gal-1) and -3 (Gal-3) in acute ischemic stroke (AIS) patients. METHODS: We enrolled 233 patients with first-ever acute ischemic stroke and 252 healthy controls in this study. The AIS severity was evaluated by National Institutes of Health Stroke Scale (NIHSS) scores. The serum Gal-1 and -3 levels were determined. All patients were followed for 1 years and the functional outcome were evaluated by modified Rankin Scale (mRS) scores. RESULTS: We found that AIS patients had higher serum Gal-1 and -3 levels than controls. The serum Gal-3 level was closely associated with the AIS severity indicated by NHSS and infarction volume. Serum Gal-3 levels were significantly higher in patients with a poor outcome indicated by mRS scores than those in patients with a good outcome. In contrast, the serum Gal-1 is not associated with the severity and outcome of acute AIS patients. Our in vitro studies show that Gal-3 knockdown with siRNA dramatically increased the culture neuron cell viability and reduced apoptosis under oxygen glucose deprivation treatment. Meanwhile, the pro-inflammatory cytokine expression decreased with the inhibition of Gal-3. CONCLUSION: Our finding provides a novel biological marker, serum Gal-3, for monitor of acute AIS patients.

10.
Article in English | MEDLINE | ID: mdl-27274755

ABSTRACT

Hirudo (Shuizhi in Chinese) is an important Chinese medicine, which possesses many therapeutic properties for the treatment of the cerebral hemorrhage and other thrombosis-related diseases. The phytochemical investigation gave more than 51 compounds including pteridines, phosphatidylcholines, glycosphingolipids, and sterols, as well as some bioactive peptides from the Shuizhi derived from three animal species recorded in the current Chinese Pharmacopoeia. The pharmacological studies on the Shuizhi have revealed various activities such as anticoagulation, antithrombosis, antiatherosclerosis, antiplatelet aggregation, antitumor and anti-inflammatory as well as hemorheology improvement, and protective effects against cerebral ischemia-reperfusion injury. However, some important issues based on the traditional uses of Shuizhi are still not clear. The aim of the present review is to provide comprehensive knowledge on the ethnopharmacology, phytochemistry, and pharmacological activities of Shuizhi. It will provide a potential guidance in exploring main active compounds of Shuizhi and interpreting the action mechanism for the further research.

11.
Eur J Clin Pharmacol ; 70(8): 941-6, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24820767

ABSTRACT

OBJECTIVE: The pharmacokinetics of lamotrigine (LTG) varies significantly among individuals and particularly among different ethnic groups. This is in part due to the presence of genetic polymorphisms affecting genes that metabolize LTG. UGT1A4 is a major metabolizing enzyme of LTG. The aim of this study was to investigate the effect of two UGT1A4 gene polymorphisms, UGT1A4 (70C > A) and UGT1A4 (142 T > G), on the levels and efficacy of LTG in Han Chinese patients with epilepsy. METHODS: The study cohort comprised 106 Han Chinese patients patients with epilepsy who were receiving LTG monotherapy. Blood samples were taken and LTG levels measured. The presence of UGT1A4 (70C > A) and UGT1A4 (142 T > G) was determined. The therapeutic efficacy of LTG at the 1-year time-point was assessed. RESULTS: All patients were homozygous for the CC genotype of UGT1A4 (70C > A), while the distribution of UGT1A4 (142 T > G) varied among patients. Two patients had a single nucleotide deletion at position 127 (UGT1A4 127delA). To evaluate the effect of the UGT1A4 (142 T > G) polymorphism on LTG pharmacokinetics, patients were divided into two groups. Group A included patients with the 142TG or 142GG polymorphism and Group B patients had the 142TT polymorphism. The normalized blood concentration and the efficacy of LTG were higher in Group B patients than in Group A patients (P < 0.05). The two patients with UGT1A4 127delA genotype had extremely high blood levels of LTG, and treatment was discontinued in one of these patients due to a severe LTG-associated rash. CONCLUSION: Patients with the UGT1A4 142TT polymorphism had a higher blood LTG concentration and better therapeutic efficacy, suggesting that this polymorphism influences LTG activity. The UGT1A4 127delA polymorphism significantly affected LTG levels and increased one of our patient's susceptibility to LTG-related adverse events.


Subject(s)
Anticonvulsants , Epilepsy , Glucuronosyltransferase/genetics , Triazines , Adult , Anticonvulsants/blood , Anticonvulsants/pharmacokinetics , Anticonvulsants/therapeutic use , Asian People , China , Epilepsy/blood , Epilepsy/drug therapy , Epilepsy/genetics , Female , Genotype , Humans , Lamotrigine , Male , Middle Aged , Polymorphism, Genetic , Treatment Outcome , Triazines/blood , Triazines/pharmacokinetics , Triazines/therapeutic use
12.
Neurol India ; 59(4): 521-6, 2011.
Article in English | MEDLINE | ID: mdl-21891926

ABSTRACT

BACKGROUND AND OBJECTIVES: Evidence from experimental and genetic studies suggest the existence of a potential link between the polymorphisms of human leukocyte antigen class II gene (HLA-DR) and ischemic stroke. This study addressed the association of HLA-DR gene with atherosclerotic cerebral infarction (ACI) in a North Chinese Han population. MATERIAL AND METHODS: The genotyping of HLA-DRB1 was determined by standard techniques based on polymerase chain reaction and sequence-specific oligonucleotides hybridization in a gene chip. RESULTS: The relative risk (RR) of HLA-DRB1 FNx01 04 and HLA-DRB1 FNx01 03 (17) in patients with ACI and their first-degree relatives were significantly higher than those in the control group (RR=2.56 and 18.77, respectively; P <0.05). In contrast, the RR of HLA-DRB1 FNx01 12 was dramatically reduced in patients with ACI in relation to healthy controls (RR=0.17; P <0.01). CONCLUSIONS: These data indicate that the polymorphisms in HLA-DRB1 may influence the risk of ACI in the North Han population of China. Further studies are necessary to validate the observation in larger samples.


Subject(s)
Asian People/genetics , Brain Infarction/genetics , Genetic Predisposition to Disease , HLA-DR Antigens/genetics , Intracranial Arteriosclerosis/genetics , Adult , Brain Infarction/complications , China/ethnology , Family Health , Female , Gene Frequency , Genome-Wide Association Study , Genotype , HLA-DRB1 Chains , Humans , Intracranial Arteriosclerosis/complications , Male , Middle Aged , Young Adult
13.
Clin Biochem ; 44(14-15): 1223-6, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21843521

ABSTRACT

OBJECTIVES: Angiotensin I-converting enzyme (ACE) plays crucial roles not only in the regulation of circulatory homeostasis but also in the pathology of carcinomas. An insertion-deletion (I/D) polymorphism in intron 16 of ACE gene was identified to be functional. We aimed to investigate the association between ACE I/D polymorphism and risk of colorectal cancer (CRC). DESIGN AND METHODS: Using genomic DNA from 241 CRC patients and 299 control subjects, we genotyped the ACE I/D polymorphism using a polymerase chain reaction analysis. RESULTS: We found that patients carrying the D allele were associated with an increased risk of developing poorly differentiated cancer and metastasis compared with those carrying the I allele (OR=1.54, 95%CI, 1.04-2.28; OR=1.56, 95%CI, 1.08-2.26, respectively), although no significant association was observed between cases and controls in overall analysis. CONCLUSIONS: These findings indicate that the ACE I/D polymorphism is likely to play a role in CRC progression.


Subject(s)
Asian People/genetics , Colorectal Neoplasms/genetics , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Aged , Case-Control Studies , Colorectal Neoplasms/pathology , Female , Gene Frequency , Genetic Predisposition to Disease , Humans , Male , Middle Aged
14.
Neurosci Lett ; 504(1): 4-8, 2011 Oct 17.
Article in English | MEDLINE | ID: mdl-21767605

ABSTRACT

Interleukin-6 (IL-6), identified as a pleiotropic inflammatory cytokine, plays important roles in the acute inflammatory response and in the modulation of the neuroimmune response. To date, large amounts of epidemiological studies have been performed to investigate the association between the IL-6 -174G/C polymorphism and Alzheimer's disease (AD) risk. Inconclusive results, however, have been reported. We aimed to assess the effect of the IL-6 -174G/C polymorphism on AD susceptibility with the use of a meta-analysis. 14 studies involving 3769 cases of AD and 9431 control subjects were identified by a search of Pubmed, Embase and ISI Web of Science databases. Crude odds ratios (ORs) with 95% confidence intervals (CIs) for the IL-6 -174G/C polymorphism and AD risk were computed using fixed- or random-effects model when appropriate. Obvious heterogeneity among studies was detected, and a borderline statistically significant association was observed between the IL-6 -174G/C polymorphism and AD risk in Caucasians (GG vs. CC: OR=1.35, 95%CI, 1.06-1.72; GG/GC vs. CC: OR=1.27, 95%CI, 1.05-1.53, respectively). After exclusion of one study, the heterogeneity disappeared and no significant association was observed between the polymorphism and AD risk. These findings indicate that the IL-6 -174G/C polymorphism may not be an independent risk factor for the development of AD.


Subject(s)
Alzheimer Disease/genetics , Genetic Predisposition to Disease/genetics , Interleukin-6/genetics , Polymorphism, Single Nucleotide , White People/genetics , Humans
15.
Chin J Traumatol ; 14(2): 100-3, 2011 Apr 01.
Article in English | MEDLINE | ID: mdl-21453576

ABSTRACT

OBJECTIVE: To observe the quality of life in patients with post-traumatic epilepsy and discuss the influencing factors. METHODS: We assessed 105 patients with post-traumatic epilepsy and 100 healthy people as control using Quality of Life Scale-31 (QOL-31), Self-rating Depressing Scale (SDS) and Self-rating Anxiety Scale (SAS), and conducted retrospective analysis on the depression, anxiety, site of trauma, control of seizure, EEG and therapeutic compliance. RESULTS: Patients with post-traumatic epilepsy scored much lower than the control group on QOL-31 (P less than 0.01), but higher than the control group on SDS and SAS (P less than 0.01). Multiple regression analysis indicated that major influencing factors on the quality of life were anxiety, therapeutic compliance, depression, poor control of epileptic seizure and site of trauma. CONCLUSIONS: The quality of life in patients with post-traumatic epilepsy has significantly declined. Doctors should pay attention to psychological and mental problems of patients with epilepsy, such as depression and anxiety, enhancing therapeutic compliance and controlling epileptic seizure, which are the keys to improving prognosis.


Subject(s)
Epilepsy, Post-Traumatic/psychology , Quality of Life , Humans , Regression Analysis , Retrospective Studies
16.
Biochim Biophys Acta ; 1584(1): 65-72, 2002 Sep 05.
Article in English | MEDLINE | ID: mdl-12213494

ABSTRACT

Phospholipase D 2 (PLD2) is the major PLD isozyme associated with the cardiac sarcolemmal (SL) membrane. Hydrolysis of SL phosphatidylcholine (PC) by PLD2 produces phosphatidic acid (PA), which is then converted to 1,2 diacylglycerol (DAG) by the action of phosphatidate phosphohydrolase type 2 (PAP2). In view of the role of both PA and DAG in the regulation of Ca(2+) movements and the association of abnormal Ca(2+) homeostasis with congestive heart failure (CHF), we examined the status of both PLD2 and PAP2 in SL membranes in the infarcted heart upon occluding the left coronary artery in rats for 1, 2, 4, 8 and 16 weeks. A time-dependent increase in both SL PLD2 and PAP2 activities was observed in the non-infarcted left ventricular tissue following myocardial infarction (MI); however, the increase in PAP2 activity was greater than that in PLD2 activity. Furthermore, the contents of both PA and PC were reduced, whereas that of DAG was increased in the failing heart SL membrane. Treatment of the CHF animals with imidapril, an angiotensin-converting enzyme (ACE) inhibitor, attenuated the observed changes in heart function, SL PLD2 and PAP2 activities, as well as SL PA, PC and DAG contents. The results suggest that heart failure is associated with increased activities of both PLD2 and PAP2 in the SL membrane and the beneficial effect of imidapril on heart function may be due to its ability to prevent these changes in the phospholipid signaling molecules in the cardiac SL membrane.


Subject(s)
Heart Failure/enzymology , Imidazolidines , Myocardium/enzymology , Phosphatidate Phosphatase/metabolism , Phospholipase D/metabolism , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Coronary Stenosis , Disease Models, Animal , Enzyme Activation/drug effects , Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology , Heart Failure/drug therapy , Heart Ventricles/drug effects , Imidazoles/therapeutic use , Male , Oleic Acid/pharmacology , Phosphatidate Phosphatase/analysis , Phosphatidylinositol 4,5-Diphosphate/pharmacology , Phospholipase D/analysis , Rats , Rats, Sprague-Dawley , Sarcolemma/drug effects , Sarcolemma/enzymology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...